 |
answer text |
<p>Chimeric Antigen Receptor T-cell (CAR-T) therapies have been available since November
2018 (acute lymphoblastic leukaemia) and December 2018 (relapsed DLBCL). The first
patients were reinfused in January 2019. Therefore, the only data we have for the
last five years is for 2019 and 2020. We do not have numbers for people treated in
trials.</p><p> </p><p>Number of people with diffuse large B-cell lymphoma that have
received CAR-T therapies in each of the last five years:</p><p> </p><table><tbody><tr><td><p>Indication</p></td><td><p>2019</p></td><td><p>2020*</p></td></tr><tr><td><p>Diffuse
large B cell lymphoma</p></td><td><p>133</p></td><td><p>Suppressed due to small numbers</p></td></tr></tbody></table><p>Note:
*Up to 21 January 2020</p><p> </p><p>Number of children with relapsed acute lymphoblastic
leukaemia that have received CAR-T therapies in each of the last five years:</p><p>
</p><table><tbody><tr><td><p>Indication</p></td><td><p>2019</p></td><td><p>2020*</p></td></tr><tr><td><p>Acute
lymphoblastic leukaemia</p></td><td><p>20</p></td><td><p>Suppressed due to small numbers</p></td></tr></tbody></table><p>Note:
*Up to 21 January 2020</p><p> </p><p>We are unable to provide the numbers of people
with relapsed diffuse large B-cell lymphoma and children with relapsed acute lymphoblastic
leukaemia that have received CAR-T therapy at each Joint Accreditation Committee ISCT-Europe
& EBMT (JACIE) accredited treatment centre treatment due to small numbers and
the possibility of patients being identified. This will be possible in the future
when the number of patients treated increases.</p><p> </p><p> </p><p> </p><p> </p>
|
|
